Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Change in Account Payables (2023 - 2026)

Nuvectis Pharma has reported Change in Account Payables over the past 4 years, most recently at -$1.6 million for Q1 2026.

  • Quarterly results put Change in Account Payables at -$1.6 million for Q1 2026, down 419.64% from a year ago — trailing twelve months through Mar 2026 was $1.7 million (up 38.12% YoY), and the annual figure for FY2025 was $3.8 million, up 1483.15%.
  • Change in Account Payables reached -$1.6 million in Q1 2026 per NVCT's latest filing, down from -$165000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.0 million in Q2 2025 and bottomed at -$1.6 million in Q1 2026.
  • Median Change in Account Payables over the past 4 years was $87000.0 (2024), compared with a mean of $137307.7.
  • The largest annual shift saw Change in Account Payables soared 2181.61% in 2025 before it crashed 419.64% in 2026.
  • Over 4 years, Change in Account Payables stood at -$721000.0 in 2023, then surged by 132.87% to $237000.0 in 2024, then plummeted by 169.62% to -$165000.0 in 2025, then crashed by 856.97% to -$1.6 million in 2026.
  • Business Quant data shows Change in Account Payables for NVCT at -$1.6 million in Q1 2026, -$165000.0 in Q4 2025, and $1.5 million in Q3 2025.